Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

被引:12
|
作者
Mostafa, Mahmoud [1 ]
Al Fatease, Adel [2 ]
Alany, Raid G. [3 ,4 ]
Abdelkader, Hamdy [2 ]
机构
[1] Minia Univ, Fac Pharm, Dept Pharmaceut, Al Minya 61519, Egypt
[2] King Khalid Univ, Coll Pharm, Dept Pharmaceut, Abha 62223, Saudi Arabia
[3] Kingston Univ London, Sch Pharm, Kingston Upon Tames KT1 2EE, England
[4] Univ Auckland, Sch Pharm, Auckland 1010, New Zealand
关键词
chronic eye diseases; inserts; implants; ocular delivery; IN-VITRO CHARACTERIZATION; VIVO PHARMACODYNAMIC EVALUATION; NANOSTRUCTURED LIPID CARRIERS; DRY-EYE; SUSTAINED-RELEASE; EX-VIVO; MACULAR DEGENERATION; OPHTHALMIC DELIVERY; HYALURONIC-ACID; AQUEOUS-HUMOR;
D O I
10.3390/pharmaceutics15061746
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases.
引用
收藏
页数:50
相关论文
共 50 条
  • [21] Recent advances in topical nano drug-delivery systems for the anterior ocular segment
    Lakhani, Prit
    Patil, Akash
    Majumdar, Soumyajit
    THERAPEUTIC DELIVERY, 2018, 9 (02) : 137 - 153
  • [22] Biomaterial Drug Delivery Systems for Prominent Ocular Diseases
    Sapowadia, Avin
    Ghanbariamin, Delaram
    Zhou, Libo
    Zhou, Qifa
    Schmidt, Tannin
    Tamayol, Ali
    Chen, Yupeng
    PHARMACEUTICS, 2023, 15 (07)
  • [23] Ocular drug delivery—eye on innovation
    Ilva D. Rupenthal
    Michael O’Rourke
    Drug Delivery and Translational Research, 2016, 6 : 631 - 633
  • [24] Advances in the topical ocular drug delivery
    Sultana, Yasmin
    Aqil, M.
    Ali, Asgar
    Samad, Abdus
    EXPERT REVIEW OF OPHTHALMOLOGY, 2007, 2 (02) : 309 - 323
  • [25] Overview of Recent Advances in Nano-Based Ocular Drug Delivery
    Liu, Li-Ching
    Chen, Yi-Hao
    Lu, Da-Wen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [26] Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals
    Adwan, Samer
    Qasmieh, Madeiha
    Al-Akayleh, Faisal
    Agha, Ahmed Saad Abdulbari Ali
    PHARMACEUTICALS, 2024, 17 (10)
  • [27] Recent developments in ocular drug delivery
    Chen, Hongming
    JOURNAL OF DRUG TARGETING, 2015, 23 (7-8) : 597 - 604
  • [28] Recent Perspectives in Ocular Drug Delivery
    Ripal Gaudana
    J. Jwala
    Sai H. S. Boddu
    Ashim K. Mitra
    Pharmaceutical Research, 2009, 26
  • [29] Recent Perspectives in Ocular Drug Delivery
    Gaudana, Ripal
    Jwala, J.
    Boddu, Sai H. S.
    Mitra, Ashim K.
    PHARMACEUTICAL RESEARCH, 2009, 26 (05) : 1197 - 1216
  • [30] Recent trends in ocular drug delivery
    Parel, JM
    Milne, PJ
    Parrish, RK
    MACULA: DIAGNOSIS, TREATMENT AND FUTURE TRENDS, 2004, : 261 - 281